HOWL – werewolf therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Citizens Jmp from a "strong-buy" rating to a "hold" rating.
Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Citigroup Inc. from a "market outperform" rating to a "market perform" rating.
Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. They now have a $1.00 price target on the stock.
Werewolf Therapeutics (NASDAQ:HOWL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Werewolf Therapeutics Announces Pipeline and Business Updates
Form 144 Werewolf Therapeutics, Filed by: UBS Oncology Impact Fund L.P.
Form 144 Werewolf Therapeutics, Filed by: MPM BioVentures 2014, L.P.
Form 144 Werewolf Therapeutics, Filed by: MPM Asset Management Investors BV2014 LLC
Form 144 Werewolf Therapeutics, Filed by: MPM BioVentures 2014 (B), L.P.
Form 144 Werewolf Therapeutics, Filed by: MPM ONCOLOGY INNOVATIONS FUND LP
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.